Abstract
Background The novel human coronavirus, SARS-CoV-2, has affected at least 218 countries worldwide. Some geographical and environmental factors are positively associated with a better or worse prognosis concerning COVID-19 disease and with lower or higher SARS-CoV-2 transmission. High altitude exposure has been associated with lower SARS-CoV-2 attack rates; nevertheless, the role of chronic high-altitude exposure on the clinical outcome of critically ill COVID-19 patients has not been studied.
Objective To compare the clinical course and outcomes of critically ill patients with COVID-19 hospitalized in two intensive care units (ICU) located at low and high altitude.
Exposure and Outcome To explore the effect of two different elevations (10 m vs 2,850 m above sea level) on COVID-19 clinical outcome and survival.
Methods A prospective cohort, two-center study in confirmed COVID-19 adult patients admitted to a low altitude (Sea level) and high altitude (2,850 m) ICU units in Ecuador was conducted. Two hundred and thirty confirmed COVID-19 patients were enrolled from March 15th to July 15th, 2020. Sociodemographic, clinical, laboratory and imaging parameters including supportive therapies, pharmacological treatments and medical complications were reported and compared between the low and high-altitude groups.
Results The median age of all the patients was 60 years, 64.8% were men and 35.2% were women. A total of 105 (45.7%) patients had at least one underlying comorbidity, the most frequent being chronic diseases, such as hypertension (33.5%), diabetes (16.5%), and chronic kidney failure (5.7%). The APACHE II scale at 72 hours was especially higher in the low-altitude group with a median of 18 points (IQR: 9.5-24.0), compared to 9 points (IQR: 5.0-22.0) obtained in the group of high altitude. There is evidence of a difference in survival in favor of the high-altitude group (p = 0.006), the median survival being 39 days, compared to 21 days in the low altitude group.
Conclusion There has been a substantial improvement in survival amongst people admitted to the high-altitude critical care unit. High altitude living was associated with improved survival, especially among patients with no comorbidities. COVID-19 patients admitted to the high-altitude ICU unit have improved severity-of-disease classification system scores at 72 hours and reported better respiratory and ventilatory profiles than the low altitude group.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work did not receive a formal grant: however, it received financial support associated with the publication fee from the University of the Americas in Quito, Ecuador.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by the Hospital IESS-Quito-Sur Internal Review Board (IRB). The request for authorization was submitted in March 1st 2020 and received ethical approval with the following identification number: ID: IESS-HG-SQ-CIE-2020-2656-M. According to good clinical practices and local regulations, identifiable data from clinical records was only accessed by the medical team that was providing treatment and care to the patients
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to the nature of the data and according to local regulation, information concerning patients results cannot be published. Nevertheless, the data that support the findings of this study are available from the corresponding author, Dr. Esteban Ortiz-Prado upon reasonable request at e.ortizprado{at}gmail.com.
List of Abbreviations
- ACE2
- Type-2 angiotensin-converting enzyme
- ARDS
- Acute Respiratory Distress Syndrome
- BMI
- Body Mass Index
- CHF
- Congestive Heart Failure
- CKD
- Chronic Kidney Disease
- COPD
- Chronic Obstructive Pulmonary Disease
- COVID-19
- Novel Coronavirus disease 2019
- CT
- Computed Tomography
- CVD
- Cerebrovascular Disease
- ICU
- Intensive care unit
- IQR
- Interquartile Range
- TB
- Tuberculosis
